Yes, 2HG can serve as a biomarker for cancers harboring IDH mutations. Elevated levels of 2HG in blood, cerebrospinal fluid, or tumor tissues can be indicative of the presence of IDH-mutant cancers. Monitoring 2HG levels can also help in assessing the response to targeted therapies, offering a non-invasive means to track disease progression and treatment efficacy.
